Get the Stockscreener App
0.4612
13.51%
0.0549
After Hours:
.45
-0.0112
-2.43%
Passage Bio Inc stock is traded at $0.4612, with a volume of 499.65K.
It is up +13.51% in the last 24 hours and down -7.58% over the past month.
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases.
See More
Previous Close:
$0.4063
Open:
$0.45
24h Volume:
499.65K
Relative Volume:
2.13
Market Cap:
$29.80M
Revenue:
-
Net Income/Loss:
$-68.80M
P/E Ratio:
-0.3942
EPS:
-1.17
Net Cash Flow:
$-59.06M
1W Performance:
+39.76%
1M Performance:
-7.58%
6M Performance:
-44.37%
1Y Performance:
-48.28%
1-Day Range:
$0.4259
$0.47
1-Week Range:
$0.3311
$0.47
52-Week Range:
$0.257
$1.33
Passage Bio Inc Stock (PASG) Company Profile
Name
Passage Bio Inc
Sector
Industry
Phone
(267) 866-0312
Address
ONE COMMERCE SQUARE, PHILADELPHIA, PA
Compare PASG with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PASG
Passage Bio Inc
|
0.4612 | 29.80M | 0 | -68.80M | -59.06M | -1.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.62 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.36 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.91 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
543.48 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Passage Bio Inc Stock (PASG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-29-24 | Resumed | Wedbush | Outperform |
| Sep-03-24 | Initiated | Rodman & Renshaw | Buy |
| Mar-08-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-19-22 | Downgrade | Goldman | Buy → Neutral |
| Jul-01-21 | Initiated | Raymond James | Outperform |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| Mar-04-21 | Upgrade | Goldman | Neutral → Buy |
| Feb-04-21 | Initiated | Guggenheim | Buy |
| Jan-25-21 | Initiated | Wedbush | Outperform |
| Jan-04-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-11-20 | Initiated | Citigroup | Neutral |
| Aug-14-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-25-20 | Downgrade | Goldman | Buy → Neutral |
| Mar-25-20 | Initiated | Chardan Capital Markets | Buy |
| Mar-24-20 | Initiated | Cowen | Outperform |
| Mar-24-20 | Initiated | Goldman | Buy |
| Mar-24-20 | Initiated | JP Morgan | Overweight |
View All
Passage Bio Inc Stock (PASG) Latest News
Passage Bio, Inc. (NASDAQ:PASG) Stake Cut by Two Sigma Investments LP - Defense World
Two Sigma Investments LP Makes New Investment in BioVie Inc. (NASDAQ:BIVI) - Defense World
10,923 Shares in Annovis Bio, Inc. (NYSE:ANVS) Bought by Two Sigma Investments LP - Defense World
American Battery Technology (NASDAQ:ABAT) Shares Purchased by Two Sigma Investments LP - Defense World
Millennium Management LLC Purchases Shares of 37,704 Nautilus Biotechnology, Inc. (NASDAQ:NAUT) - Defense World
Fierce Biotech Layoff Tracker 2025: ADC Tx lets go of 30% of workers; Vertex sheds 125 staffers - Fierce Biotech
Squarepoint Ops LLC Has $36,000 Stake in Passage Bio, Inc. (NASDAQ:PASG) - Defense World
Semrush Holdings, Inc. (NASDAQ:SEMR) Shares Purchased by Bank of America Corp DE - Defense World
Lumina Gold (OTCMKTS:LMGDF) Trading Down 0.3% – Here’s Why - Defense World
Obsidian Energy (OTCMKTS:OBELF) Shares Up 2.7% – Here’s Why - Defense World
Carbios SAS (OTCMKTS:COOSF) Stock Price Up 5% – Here’s Why - Defense World
Suncrest Bank (OTCMKTS:SBKK) Shares Up 1% – Should You Buy? - Defense World
Color Star Technology (NASDAQ:CSCW) Trading 0.5% Higher – Here’s What Happened - Defense World
Inventiva (NASDAQ:IVA) Stock Price Up 0.8% – Here’s Why - Defense World
Fury Gold Mines (NYSEAMERICAN:FURY) Stock Price Down 3.2% – Here’s Why - Defense World
Nano Magic (OTCMKTS:NMGX) Shares Up 5% – What’s Next? - Defense World
Jane Street Group LLC Grows Holdings in Passage Bio, Inc. (NASDAQ:PASG) - Defense World
Pre-market Movers: BDTX, CRGX, PASG, RGC... - RTTNews
Layoff Tracker: Capsida Downsizes as Part of Shift to Clinical-Stage Company - BioSpace
Passage Bio, Inc. (NASDAQ:PASG) Shares Purchased by Northern Trust Corp - Defense World
Two Sigma Investments LP Has $1.93 Million Stake in Haleon plc (NYSE:HLN) - Defense World
Passage Bio Adopts Key Proposals at Annual Meeting - TipRanks
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Cuts Stock Position in Talkspace, Inc. (NASDAQ:TALK) - Defense World
D. E. Shaw & Co. Inc. Increases Holdings in 908 Devices Inc. (NASDAQ:MASS) - Defense World
VintaBio Showcases Breakthrough Gene Therapy Manufacturing Platform - MyChesCo
Metachromatic Leukodystrophy Pipeline 2025: Groundbreaking - openPR.com
GM1 Gangliosidosis Market: Epidemiology, Therapies, - openPR.com
Guggenheim Adjusts Price Target for Passage Bio (PASG) | PASG St - GuruFocus
Cubist Systematic Strategies LLC Grows Holdings in Intevac, Inc. (NASDAQ:IVAC) - Defense World
Cabaletta Bio Updates Progress on RESET-Myositis Trial and Regulatory Milestones - MyChesCo
Passage Bio Reports Q1 2025 Financial Results and Highlights Progress in Gene Therapy Development - MSN
Wedbush Issues Pessimistic Estimate for Passage Bio Earnings - Defense World
Gm1 Gangliosidosis Treatment Market in 2025 Detailed Study - openPR.com
Dimensional Fund Advisors LP Has $1.14 Million Stock Holdings in Traeger, Inc. (NYSE:COOK) - Defense World
TransAct Technologies Incorporated (NASDAQ:TACT) Shares Acquired by Dimensional Fund Advisors LP - Defense World
Passage Bio, Inc. (NASDAQ:PASG) Shares Acquired by Tower Research Capital LLC TRC - Defense World
Tower Research Capital LLC TRC Acquires 7,927 Shares of The E.W. Scripps Company (NASDAQ:SSP) - Defense World
Braskem Marks 15 Years of I’m green Bio-Based Portfolio with Expanded Production - MyChesCo
Passage Bio Reports Q1 2025 Financial Results - TipRanks
Wedbush Adjusts Price Target on Passage Bio to $3 From $4, Maintains Outperform Rating - marketscreener.com
Passage Bio Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Passage Bio Q1 Income From Operations USD -16.459 Million - marketscreener.com
Passage Bio (PASG) Advances Phase 1/2 Trial for PBFT02, Eyes Fut - GuruFocus
Passage BIO, Inc. SEC 10-Q Report - TradingView
Passage Bio Reports First Quarter 2025 Financial Results and Provides Recent Business Highlights - GlobeNewswire
Passage Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Soleno Therapeutics Announces Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at ISPOR 2025 - The Manila Times
Passage Bio (PASG) Expected to Announce Earnings on Tuesday - Defense World
2025 Q1 Job Market Report: Quarterly Job Postings Live Declined as Applications Spiked - BioSpace
Annovis Bio Appoints Hui Liu as Director of Biostatistics - MyChesCo
Orbimed Advisors LLC Reduces Stake in Passage Bio Inc: A Strategic Portfolio Adjustment - GuruFocus
Passage Bio Inc Stock (PASG) Financials Data
Revenue
Net Income
Cash Flow
EPS
Passage Bio Inc Stock (PASG) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 10% Owner |
Jun 26 '25 |
Sale |
0.33 |
213,257 |
70,375 |
6,066,343 |
| ORBIMED ADVISORS LLC | 10% Owner |
Jun 25 '25 |
Sale |
0.33 |
138,800 |
45,804 |
6,279,600 |
0.68%
0.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):